Overview

A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)

Status:
Withdrawn
Trial end date:
2020-06-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the investigational treatment (maralixibat) is safe and effective in pediatric participants with Progressive Familial Intrahepatic Cholestasis (PFIC).
Phase:
Phase 3
Details
Lead Sponsor:
Mirum Pharmaceuticals, Inc.
Shire